title: Expression of E-cadherin and B-cell lymphoma 2 in oral cancer: A ratio-based planning for targeted therapy.
abstract: BACKGROUND
  Oral cancer is known to be governed by the antiapototic and loss of cell adhesion properties which dictate its progression.
  
  
  OBJECTIVE
  To study the immunexpression of E-cadherin and Bcl-2 in varying TNM stages and histopathological grades of OSCC.
  
  
  METHODS
  11 cases of well differentiated, 10 cases of moderately differentiated and 11 cases of poorly differentiated OSCC were studied immunohistochemically using archival paraffin embedded tissue specimens.
  
  
  METHODS
  Differences between the different variables were analyzed using ANOVA test, Kruskal-Wallis test and post hoc test followed by Bonferroni test. The resulting data was analyzed using SPSS software version 19.
  
  
  RESULTS
  The expression of Bcl-2 and E cadherin immunopositivity was associated positively with tumor grade, high T category and Histopathological grades.
  
  
  CONCLUSIONS
  The results of this study points to the significance of cell proliferation and invasion as a major determinant of prognosis in OSCC.
authors.affiliation: Department of Oral and Maxillofacial Pathology and Microbiology, ITS Dental Collge, Ghaziabad, Uttar Pradesh, India.
authors.forename: Nikita
authors.initials: N
authors.lastname: Gulati
authors.affiliation: Department of Oral and Maxillofacial Pathology and Microbiology, ITS Dental Collge, Ghaziabad, Uttar Pradesh, India.
authors.forename: Ajit Singh
authors.initials: AS
authors.lastname: Rathore
authors.affiliation: Department of Oral and Maxillofacial Pathology and Microbiology, ITS Dental Collge, Ghaziabad, Uttar Pradesh, India.
authors.forename: Saurabh
authors.initials: S
authors.lastname: Juneja
authors.affiliation: Department of Oral and Maxillofacial Pathology and Microbiology, ITS Dental Collge, Ghaziabad, Uttar Pradesh, India.
authors.forename: Priyanka
authors.initials: P
authors.lastname: Rastogi
mesh_terms: D015820:Cadherins / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000473:pathology*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics / Q000276:immunology / Q000473:pathology; D004252:DNA Mutational Analysis; D003906:Developing Countries; D006801:Humans; D007194:India; D058990:Molecular Targeted Therapy; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000276:immunology / Q000473:pathology*; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis* / Q000037:antagonists & inhibitors / Q000235:genetics*
chemical_list: C000595707:BCL2 protein, human; D015820:Cadherins; D019253:Proto-Oncogene Proteins c-bcl-2